Therapeutic Potential of Senolytics in Cardiovascular Disease

Emily Dookun, João F. Passos, Helen M. Arthur, Gavin D. Richardson

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Ageing is the biggest risk factor for impaired cardiovascular health, with cardiovascular disease being the leading cause of death in 40% of individuals over 65 years old. Ageing is associated with both an increased prevalence of cardiovascular disease including heart failure, coronary artery disease, and myocardial infarction. Furthermore, ageing is associated with a poorer prognosis to these diseases. Genetic models allowing the elimination of senescent cells revealed that an accumulation of senescence contributes to the pathophysiology of cardiovascular ageing and promotes the progression of cardiovascular disease through the expression of a proinflammatory and profibrotic senescence-associated secretory phenotype. These studies have resulted in an effort to identify pharmacological therapeutics that enable the specific elimination of senescent cells through apoptosis induction. These senescent cell apoptosis-inducing compounds are termed senolytics and their potential to ameliorate age-associated cardiovascular disease is the focus of this review.

Original languageEnglish (US)
Pages (from-to)187-196
Number of pages10
JournalCardiovascular Drugs and Therapy
Issue number1
StatePublished - Feb 2022


  • Atherosclerosis
  • Cardiovascular
  • Inflammation
  • Remodelling
  • Senescence
  • Senolytic

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)


Dive into the research topics of 'Therapeutic Potential of Senolytics in Cardiovascular Disease'. Together they form a unique fingerprint.

Cite this